Drug Abuse Articles & Analysis
19 news found
“The data shared today validate our clinical efforts to advance cebranopadol and reinforce the potential of this investigational therapy to contribute to a future where pain can be managed without further exacerbating the impact of drug addiction.” HAP studies are required prior to U.S. Food and Drug Administration (FDA) approval in therapeutic ...
Technologies like our unique Translational Index™, which synthesizes the potential for clinical success of any drug candidate, enable smarter decisions about how to advance drug asset programs and ultimately improve the lives of patients in need.” Earlier this year, VeriSIM was awarded a grant from the National Institute on Drug ...
Food and Drug Administration (FDA) has granted its lead compound, ENA-001, Orphan Drug Designation for the treatment of Apnea of Prematurity (AoP). ...
The Funding Will Accelerate Development of an Intramuscular Formulation of ENA-001, a Novel Agnostic Respiratory Stimulant, for the Potential Treatment of Community Drug Overdose and as a Medical Countermeasure for Mass Casualty Events. ...
The study, conducted with the support of Emory and Georgia Tech University, was sponsored by a grant from the National Institute on Drug Addiction (NIDA), part of the National Institutes of Health (NIH), through NIH Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative. Substance use is an escalating crisis in the United States, with opioid-related ...
Called the COPA system, the proprietary, hand-held drug dispensing device is meant to provide at-home methadone administration as part of treatment for opioid use disorder (OUD). ...
ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity Approval for post-operative respiratory depression expected in 2026 and community drug overdose thereafter ENA-001 works peripherally by inhibiting Big Potassium (BK) ion channels in the carotid bodies, which are located in the ...
(Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that the National Institute on Drug Abuse, part of the National Institutes of Health (NIH), has awarded Columbia University a multi-year NIDA grant to fund clinical ...
Berkshire Biomedical Corporation ("Berkshire" or "the Company"), focused on developing its proprietary, hand-held, automated personalized drug dispensing technology to enhance patient wellness, today announced that it has been awarded the first phase of a two-phase Fast-Track Small Business Innovation Research (SBIR) grant (1R44DA057185-01) from the National Institutes of ...
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). Funding from the grant will be used to further the ...
VeriSIM Life (VeriSIM), the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, announced today it has been awarded a $312,310 grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to fund AI-driven development of medications for ...
Overall, infective endocarditis is just one of many applications of our technology in cardiac surgery and is a much smaller opportunity than the removal of antithrombotic drugs during cardiothoracic surgery, for which we have specific approvals in the E.U., two U.S. ...
Thermo Fisher Scientific, the world leader in serving science, today announced a partnership with Mindray, a leading global developer, manufacturer and supplier of medical devices, to make available to customers two clinical chemistry analyzers in the United States (U.S.) and Canada for drug screening in clinical and drug court laboratories. "Systematically and ...
With the PCT Patent, along with Kannalife’s novel lead drug candidate KLS-13019 and its other novel therapeutic agents like Atopidine™, Kannalife now has near-global coverage in the top pharmaceutical markets in the world. ...
(OTCQB: KLFE) (“Kannalife” or the “Company”), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today that it has completed its phase 1 study funded by a grant (1R41DA044898-01) from the National Institutes of Health’s (NIH) National Institute on Drug Abuse (NIDA). The ...
” Results from Kannalife’s pre-clinical research funded by a grant from the National Institute on Drug Abuse were recently published in the Journal of Molecular Neuroscience (JOMN), describing in detail the siRNA knockdown and mechanism of action for both KLS-13019 and cannabidiol (CBD) in the potential treatment of chemotherapy-induced peripheral ...
Gas flow systems serve myriad purposes around the world. They are used to calibrate gas chromatographs (GC) in laboratory and analytical facilities and have been widely employed in the mixing, blending, and delivery of appropriate medical gas mixtures. Ground-breaking clinical research into the interaction between distinct gases and cellular behaviour has also benefits from the availability of ...
"Researchers from the 88 projects supported by the program, including those from this recent series of papers, have propelled the development of new epigenomic technologies," said John Satterlee, Ph.D., co-coordinator of the Roadmap Epigenomics Program, and program director at the National Institute on Drug Abuse (NIDA), part of NIH. Satterlee added that the work ...
H3Africa is also supported by several institutes and centers at NIH, including the National Human Genome Research Institute (NHGRI), the National Institute of Allergy and Infectious Diseases, The Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute of Allergy and Infectious Diseases, the National Institute on Drug ...